HOOK | tickerfilter.com

Fundamental analysis

31%

Profitability 25%

Dept financing 9%

Liquidity 75%

Performance 32%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.08%

1 Month

2.17%

3 Months

-50.66%

6 Months

-59.74%

1 Year

196.06%

2 Year

88.09%

Key data

Stock price

$1.88

P/E Ratio

0.00

DAY RANGE

$1.84 - $1.94

EPS

-$3.04

52 WEEK RANGE

$0.50 - $6.62

52 WEEK CHANGE

$178.93

MARKET CAP

51.835 M

YIELD

N/A

SHARES OUTSTANDING

9.655 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.14

PUBLIC FLOAT

AVERAGE 10 VOLUME

$45,363

AVERAGE 30 VOLUME

$225,275

Company detail

CEO: Jörn Aldag
Region: US
Website: www.hookipapharma.com
Employees: 160
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

HOOK - HOOKIPA Pharma Inc.